Advertisement

Topics

Companies Related to "Characterization of Circulating Tumor Cells (CTCs) to Direct Pre-Operative and Systemic Therapy in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer" [Most Relevant Company Matches] RSS

19:15 EST 18th February 2019 | BioPortfolio

Here are the most relevant search results for "Characterization of Circulating Tumor Cells (CTCs) to Direct Pre-Operative and Systemic Therapy in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer" found in our extensive corporate database of over 50,000 company records.

Showing "Characterization Circulating Tumor Cells CTCs Direct Operative Systemic" Companies 1–25 of 1,900+

Extremely Relevant

AdnaGen AG

AdnaGen's diagnostics detect circulating tumor cells in tumor patients. Because tumor cells survive only hours in the bloodstream, there must be an active source, e.g. a relapse or a metastasis. Therefore, the presence of circulating tumor cells is an unfavorable indicator for the progress of the tumor disease. AdnaGen's proprietary 'combination-of-combinations-principle' allows the reliable and v...


Immunicon Corporation

Immunicon is developing and commercializing diagnostic and research products for rare cell analysis and molecular research, with an initial focus on cancer. Our instruments and reagents are used to capture, count and characterize rare cells including circulating tumor cells (CTCs) in cancer patients or circulating endothelial cells (CECs), which are elevated in a variety of diseases. Our goal is t...

RareCyte Inc.

RareCyte is a life science research and diagnostic development company focused on characterizing and isolating rare cells in the blood. RareCyte is dedicated to bringing its innovative technology to the Life Sciences research, drug development, and diagnostic markets providing new tools to answer difficult questions related to cancer and cardiovascular dis...


Epic Sciences, Inc.

Epic Sciences, Inc. (www.epicsciences.com) is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells (“CTCs”). Epic is ...

ScreenCell

ScreenCell, headquartered in Paris, France is a privately held company dedicated to provide products, protocols and training support for cancer research facilities to characterize Circulating Tumor Cells and other rare cells in biological specimens. For more information please visit www.screencell.com

Relevant

Oncomatrix

Oncomatrix is focused on the development of new biopharmaceuticals targeting the tumor stroma. This innovative approach aims not to attack the tumor cells directly but rather the cells supporting the growth and invasiveness of the tumor.

STEMTech HealthSciences Inc.

Founded in 2005 and headquartered in San Clemente, California, STEMTech HealthSciences Inc. is a pioneer in stem cell nutrition. Its patented flagship product, StemEnhance(R), co-invented by neurophysiologist Christian Drapeau and immunologist Dr. Gitte Jensen, was shown in a recent scientific study to promote an average 25% increase in the number of circulating adult stem cells. Recent scientific...

AC Vaccine technology

The AC Vaccine technology is a therapuetic treatment based on the concept of haptenization. This idea has a long history, beginning with the work of the immunologist and Nobel laureate Karl Landsteiner in the 1920’s. He and other scientists showed in animal models that attaching a small chemical (a hapten) to a protein allowed that protein to be recognized by the immune system even if the anim...

APO-T B.V. and LinXis B.V.

APO-T is a biopharmaceutical company focused on the development and commercialization of proprietary biotherapeutics for oncology. APO-T has developed fully-human antibodies and antibody fragments that target any tumor cell that expresses a MAGE-A peptide in the context of MHC-1. Many different kinds of tumors expose this MAGE-MHC-1 peptide complex. They a...

Specific Technologies

Specific Technologies has developed in vitro systems for rapid identification of cells, and is applying this fundamental new platform to the detection and characterization of microorganisms causing blood infection. The company is also exploring applications for antibiotic drug discovery and the identification of tumor cells by type and mutation variant. Th...

Targeted Diagnostics and Therapeutics

TDT has emerged as a leader in the development of innovative molecular diagnostics and therapeutics that can improve the quality of life of patients with colorectal cancer and gastrointestinal malignancies. Focused on innovative research and cutting edge technology, TDT has developed highly specific tests to detect colorectal cancer cells in lymph nodes from patients who have undergone surgical st...

Cell Works Incorporated

Cell Works Inc. is an early-stage biomedical company located in Baltimore, Maryland, basing their initial products on research conducted at The Johns Hopkins University (JHU). Cell Works has exclusively licensed certain cell isolation technology from JHU on a worldwide basis. This technology license currently incorporates one patent, one patent application, and related international patent applica...

Direct Therapeutics, Inc.

Direct Therapeutics, Inc. is a development-stage pharmaceutical company using its patented Solvent-Facilitated Perfusion technology to create new drugs for the localized and regional treatment of solid-tumor cancers. Our products are designed for direct injection to target tissue with minimal invasion of healthy tissue. They contain active ingredients in organic solvent vehicles that facilitate th...

IRX Therapeutics, Inc.

IRX Therapeutics is a clinical-stage company developing novel immunotherapies focused on reducing the immune suppression that is seen in the cancer tumor micro-environment, restoring immune function, and activating a coordinated immune response against the tumor. The lead candidate, IRX-2, is a proprietary therapeutic containing numerous active cytokine co...

Triumvira Immunologics

Triumvira is developing an engineered T-cell technology called the T-Cell Antigen Coupler (TAC), developed in the laboratory of Dr. Jonathan Bramson at McMaster University in Hamilton, Ontario, and is designed to activate T-cells through the T-cell receptor complex. In multiple liquid and solid tumor animal models, TAC-T cells outperform CAR-T cells, with ...

Targeted Diagnostics & Therapeutics, Inc

TDT has emerged as a leader in the development of innovative molecular diagnostics and therapeutics that can improve the quality of life of patients with colorectal cancer and gastrointestinal malignancies. Focused on innovative research and cutting edge technology, TDT has developed highly specific tests to detect colorectal cancer cells in lymph nodes from patients who have undergone surgical st...

FLX Bio, Inc.

FLX475 is a best-in-class oral, small molecule antagonist of CCR4. CCR4 ligands are elevated in multiple tumor types when compared to normal tissue. In preclinical studies, FLX475 inhibited tumor growth and increased tumor regression. In addition, FLX475 enhanced the antitumor effects of various checkpoint inhibitors including anti-PD-L1 and anti-CTLA4 ant...

Oncolytics

The Company's technologies are based on discoveries arising from research conducted at the University of Calgary. Dr. Coffey, VP Product Development for the Company was instrumental in these discoveries, and continues to be instrumental in the product development process. The Company was formed in 1998, to explore the natural oncolytic capability of the reovirus, a virus that preferentially replic...

OncoMed Pharmaceuticals Inc.

OncoMed Pharmaceuticals is pioneering the development of novel therapeutics that target a new class of solid tumor cells, known as "cancer stem cells". The company's technology is based on a recent discovery by its co-founders that cancer stem cells are uniquely responsible for the growth and proliferation of tumors. We are leveraging our advanced understanding of cancer stem cells to identify the...

Phoenix Biotechnology, Inc.

Phoenix Biotechnology, Inc., a San Antonio, Texas based biotechnology company, was incorporated in Texas in 2003 to develop promising agents with minimal or no side effects for targeted therapy of malignant tumor growth. Targeted therapy has recently become the focus in the medical community for the treatment of oncologic diseases. Pharmaceutical companies...

Rigontec

Rigontec is the leader in RIG-I targeting therapeutics. Utilizing our proprietary RIG-I agonist platform, we harness one of the most essential pathways in the innate immune system to pioneer a novel immuno-oncology treatment approach. Rigontec’s proprietary agonists specifically activate RIG-I, inducing both immediate and long-term anti-tumor immunity...

Sonrgy, Inc.

Sonrgy is a preclinical stage biotechnology company based in San Diego, California that is developing a targeted chemotherapy delivery platform to improve survival and quality of life for millions of cancer patients. Sonrgy’s tiny nanocarriers safely transport potent chemotherapy drugs to cancer tumors and release high doses on command in response to a focus...

Checkmate Pharmaceuticals, Inc.

Checkmate Pharmaceuticals is a research and development company pursuing a novel approach to specifically activating the innate arm of the immune system to recognize and ultimately destroy tumor cells. The company is leveraging their expertise and the vast body of knowledge in the field of CpG oligonucleotides and is validating an approach that will combine ...

ActoKine Therapeutics

Cancer therapy using cytotoxic drugs or radiation has negative side effects on normal cells. To date, the pharmaceutical industry has not been able to produce a drug that can provide the dual functions of protecting normal cells while sensitizing tumor cells to cancer therapy. With consultation and guidance from industry experts, ActoKine will collaborate with international drug companies and inst...

Lifeblood Medical,Inc

We carry an extensive line of high quality serum and reagents to the research community at competitive prices. Our products include Serum (including United States and Australian Fetal Bovine Serum), Serum Enhancers (DMEM and RPMI), Antibiotics, Specialty Media and Customized Applications. Our full line of proprietary products will consist of LIFOR® and its derivatives, which will be targeted towa...


More From BioPortfolio on "Characterization of Circulating Tumor Cells (CTCs) to Direct Pre-Operative and Systemic Therapy in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks